Adalimumab

Essential medicine status

Section: 29. Medicines for diseases of joints > 29.3. Medicines for juvenile joint diseases

EMLc | ATC codes: L04AB04

Indication	Juvenile idiopathic arthritis ICD11 code: FA24.Z
INN	Adalimumab
Medicine type	Biological agent
List type	Complementary
Additional notes	EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.
Formulations	**Parenteral > General injections > SC:** 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)
EML status history	First added in 2019 (TRS 1021) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	certolizumab pegol (ATC codes: L04AB05) etanercept (ATC codes: L04AB01) golimumab (ATC codes: L04AB06) infliximab (ATC codes: L04AB02)
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Read more about patents.
Tags	Biological
Wikipedia	Adalimumab
DrugBank	Adalimumab

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc. Listing of adalimumab for the indication of juvenile idiopathic arthritis was transferred from Section 8.1 (Immunomodulators for non-malignant disease) to Section 29.3 (Juvenile joint diseases).